<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074319</url>
  </required_header>
  <id_info>
    <org_study_id>RECOVERY-001</org_study_id>
    <nct_id>NCT02074319</nct_id>
  </id_info>
  <brief_title>RCT of Methotrexate Added to Treatment As Usual in Schizophrenia</brief_title>
  <acronym>RECOVERY</acronym>
  <official_title>A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbasi Shaheed Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karwan e Hayat, Karachi, Pakistan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Behavioural Sciences, Karachi, Pakistan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the this study is to evaluate the effectiveness of methotrexate added to treatment
      as usual on positive and negative symptoms, cognitive and social functioning and quality of
      life of patients suffering from schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to test the prediction that addition of methotrexate to treatment
      as usual (TAU) for patients with schizophrenia will result in following outcomes:

        -  Primary:

             -  improvement in negative symptoms

             -  improvement in positive symptoms

        -  Secondary:

             -  improvement in social functioning

             -  improvement in cognitive functions

             -  acceptability and tolerability of methotrexate added to TAU A total 72 participants
                (36 participants in intervention group and 36 in control group) meeting inclusion
                criteria of the study will be recruited and randomized in study in two arms.
                Research assistants and participating psychiatrists will assess participants for
                eligibility criteria. After providing detailed information regarding study by using
                patient information sheet, written informed consent will be taken from
                participants. Trained research assistant will asses participants at baseline, 2, 4,
                6 and 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale PANSS</measure>
    <time_frame>3 months</time_frame>
    <description>PANSS is an assessment measures to assess severity of symptoms of schizophrenia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CogState</measure>
    <time_frame>3 months</time_frame>
    <description>Measuring all seven domains recommended by MATRICS (NIMH initiative). These domains include speed processing, attention/vigilance, Working memory (nonverbal &amp; verbal), verbal learning, visual learning, reasoning and problem solving and social cognitions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Social Functioning Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Self-rating questionnaire assessing social functioning in 7 domains.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate 10 mg once a week orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Treatment as usual or standard treatment for psychosis will be common in all arms</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent, indicating that the subject understood the purpose of and
             procedures required for the study, before the initiation of any study specific
             procedures

          -  Aged 18 to 35 years

          -  Diagnostic and Statistical Manual-IV (DSM-IV) diagnosed first episode psychosis,
             schizophrenia, schizoaffective disorder, psychosis not otherwise specified or
             schizophreniform disorder.

          -  First episode (within first 5 years of diagnosis)

          -  Competent and willing to give informed consent

          -  Medication remained stable 4 weeks prior to baseline.

          -  Able to take oral medication and likely to complete the required evaluations.

          -  Female participants of child bearing capability must be willing to use adequate
             contraceptives for the duration of the study, and, willing to have a pregnancy test
             pre treatment and at ten weekly intervals while on study medication.

               1. Adequate contraception is defined as use of contraceptive double barrier system
                  (i.e. condom and spermicide) or contraceptive implant, oral contraceptive or
                  injected depot contraceptive plus other form of contraceptive i.e. condom.
                  Females will be considered incapable of child bearing if they are one year
                  post-menopausal or irreversibly surgically sterilised.

        Exclusion Criteria:

          -  Violation of any inclusion criteria

          -  Failure to perform screening or baseline examinations

          -  Relevant ICD 10 organic brain disease or neurological diagnoses

          -  Patients with liver disease

          -  Patients who will meet the criteria for a DSM-IV TR diagnosis of alcohol or substance
             abuse (other than for nicotine) within the last month or the criteria for DSM-IV TR
             alcohol or substance dependence (other than for nicotine) within the last 6 months

          -  Any change of psychotropic medications within the previous 4 weeks

          -  Recreational drugs or alcohol abuse

          -  Pregnant or lactating women and those of reproductive age without adequate
             contraception

          -  Relevant medical illness will be determined in the first instance by asking the
             patients mental health care team if the patient has any medical condition/problems.
             After consent has been obtained the research nurse/ research doctor will then have
             access to the patients' notes and will assess patient eligibility to take part in the
             clinical trial by scrutinising the patients' past medical history, most recent blood
             results, electrocardiograms, as well as any physical tests that have been performed on
             the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Imran B Chaudhry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abasi Shaheed Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civil hospital Karachi</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Behavioural Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karwn e Hayat</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://pill.org.pk</url>
    <description>Website of Pakistan Institute of Learning and Living</description>
  </link>
  <reference>
    <citation>Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G, Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012 Sep;26(9):1185-93. doi: 10.1177/0269881112444941. Epub 2012 Apr 23.</citation>
    <PMID>22526685</PMID>
  </reference>
  <reference>
    <citation>Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci. 2008 Dec 17;28(51):13957-66. doi: 10.1523/JNEUROSCI.4457-08.2008.</citation>
    <PMID>19091984</PMID>
  </reference>
  <reference>
    <citation>Bernstein HG, Steiner J, Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother. 2009 Jul;9(7):1059-71. doi: 10.1586/ern.09.59. Review.</citation>
    <PMID>19589054</PMID>
  </reference>
  <reference>
    <citation>Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R, Mawrin C, Schmitt A, Jordan W, Müller UJ, Bernstein HG, Bogerts B, Steiner J. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun. 2012 Nov;26(8):1273-9. doi: 10.1016/j.bbi.2012.08.005. Epub 2012 Aug 14.</citation>
    <PMID>22917959</PMID>
  </reference>
  <reference>
    <citation>Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005 Jun;57(2):163-72. Review.</citation>
    <PMID>15914465</PMID>
  </reference>
  <reference>
    <citation>Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009 Nov;50(11):1801-7. doi: 10.2967/jnumed.109.066647. Epub 2009 Oct 16.</citation>
    <PMID>19837763</PMID>
  </reference>
  <reference>
    <citation>Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006 Nov;20(6):532-45. Epub 2006 Apr 3. Review.</citation>
    <PMID>16580814</PMID>
  </reference>
  <reference>
    <citation>Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990 Aug 18;336(8712):392-5.</citation>
    <PMID>1974941</PMID>
  </reference>
  <reference>
    <citation>Gong K, Zhang Z, Sun X, Zhang X, Li A, Yan J, Luo Q, Gao Y, Feng Y. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J. 2006 Jan;151(1):62-8.</citation>
    <PMID>16368293</PMID>
  </reference>
  <reference>
    <citation>Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005 Feb;114(2):154-63.</citation>
    <PMID>15639649</PMID>
  </reference>
  <reference>
    <citation>Mansur RB, Zugman A, Asevedo EM, da Cunha GR, Bressan RA, Brietzke E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci. 2012 Jun;66(4):247-60. doi: 10.1111/j.1440-1819.2012.02354.x. Review.</citation>
    <PMID>22624729</PMID>
  </reference>
  <reference>
    <citation>Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011 Oct 1;70(7):663-71. doi: 10.1016/j.biopsych.2011.04.013. Epub 2011 Jun 8.</citation>
    <PMID>21641581</PMID>
  </reference>
  <reference>
    <citation>Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65. Review.</citation>
    <PMID>19579286</PMID>
  </reference>
  <reference>
    <citation>Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcón GS. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994 Dec 1;121(11):833-41.</citation>
    <PMID>7978695</PMID>
  </reference>
  <reference>
    <citation>Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012 Apr;279(8):1375-85. doi: 10.1111/j.1742-4658.2012.08551.x. Epub 2012 Mar 27. Review.</citation>
    <PMID>22404766</PMID>
  </reference>
  <reference>
    <citation>Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008 Apr 15;63(8):801-8. Epub 2007 Nov 19.</citation>
    <PMID>18005941</PMID>
  </reference>
  <reference>
    <citation>Procter A. Enhancement of recovery from psychiatric illness by methylfolate. Br J Psychiatry. 1991 Aug;159:271-2.</citation>
    <PMID>1773245</PMID>
  </reference>
  <reference>
    <citation>Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13481-6. Epub 2002 Oct 1.</citation>
    <PMID>12359872</PMID>
  </reference>
  <reference>
    <citation>Schulte-Herbrüggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol. 2005 Mar;160(1-2):204-9. Epub 2004 Dec 22.</citation>
    <PMID>15710474</PMID>
  </reference>
  <reference>
    <citation>van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008 Nov 1;64(9):820-2. doi: 10.1016/j.biopsych.2008.04.025. Epub 2008 Jun 4.</citation>
    <PMID>18534557</PMID>
  </reference>
  <reference>
    <citation>Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004 Mar;43(3):267-71. Epub 2004 Jan 6. Review.</citation>
    <PMID>14963199</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Zhao P, Li A, Lv X, Gao Y, Sun H, Ding Y, Liu J. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm. 2009;2009:389720. doi: 10.1155/2009/389720. Epub 2009 Oct 26.</citation>
    <PMID>19884981</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <last_update_submitted>September 19, 2015</last_update_submitted>
  <last_update_submitted_qc>September 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Anti-Inflammatory</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Psychosis Not Otherwise Specified</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

